VSTM2L is a promising therapeutic target and a prognostic soluble-biomarker in cholangiocarcinoma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The aim of the present study is to provide a rational backgroundfor silencing the V-set and transmembrane domain containing2 like (VSTM2L) in consort with recognising solubleVSTM2L against cholangiocarcinoma. A therapeutic target againstcholangiocarcinoma was selected using iterative patient partitioning(IPP) calculation, and it was verified by in vitro and insilico analyses. VSTM2L was selected as a potential therapeutictarget against cholangiocarcinoma. Silencing the VSTM2L expressionsignificantly attenuated the viability and survival ofcholangiocarcinoma cells through blockade of the intracellularsignalling pathway. In silico analysis showed that VSTM2L affectedthe positive regulation of cell growth in cholangiocarcinoma. Liptak’s z value revealed that the expression of VSTM2Lworsened the prognosis of cholangiocarcinoma patients. In addition,soluble VSTM2L was significantly detected in the wholeblood of cholangiocarcinoma patients compared with that ofhealthy donors. Our report reveals that VSTM2L might be thepotential therapeutic target and a soluble prognostic biomarkeragainst cholangiocarcinoma.
Abstract
The aim of the present study is to provide a rational backgroundfor silencing the V-set and transmembrane domain containing2 like (VSTM2L) in consort with recognising solubleVSTM2L against cholangiocarcinoma. A therapeutic target againstcholangiocarcinoma was selected using iterative patient partitioning(IPP) calculation, and it was verified by in vitro and insilico analyses. VSTM2L was selected as a potential therapeutictarget against cholangiocarcinoma. Silencing the VSTM2L expressionsignificantly attenuated the viability and survival ofcholangiocarcinoma cells through blockade of the intracellularsignalling pathway. In silico analysis showed that VSTM2L affectedthe positive regulation of cell growth in cholangiocarcinoma. Liptak’s z value revealed that the expression of VSTM2Lworsened the prognosis of cholangiocarcinoma patients. In addition,soluble VSTM2L was significantly detected in the wholeblood of cholangiocarcinoma patients compared with that ofhealthy donors. Our report reveals that VSTM2L might be thepotential therapeutic target and a soluble prognostic biomarkeragainst cholangiocarcinoma.
참고문헌 (19)
- Khan SA, "Cholangiocarcinoma", Lancet, 366, pp.1303~1314 (2005)
- Bragazzi MC, "New insights into cholangiocarcinoma : multiple stems and related cell lineages of origin", Ann Gastroenterol, 31, pp.42~55 (2018)
- Patel T, "Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States", Hepatology, 33, pp.1353~1357 (2001)
- Malhi H, "Cholangiocarcinoma : modern advances in understanding a deadly old disease", J Hepatol, 45, pp.856~867 (2006)
- Khan SA, "Rising trends in cholangiocarcinoma : is the ICD classification system misleading us?", J Hepatol, 56, pp.848~854 (2012)
- Zhang S, "Pan-cancer analysis reveals the multidimensional expression and prognostic and immunologic roles of VSTM2L in cancer", Front Mol Biosci, 8, pp.792154~ (2021)
- Rossini L, "VSTM2L is a novel secreted antagonist of the neuroprotective peptide Humanin", FASEB J, 25, pp.1983~2000 (2011)
- Liu H, "High expression of VSTM2L induced resistance to chemoradiotherapy in rectal cancer through downstream IL-4 signaling", J Immunol Res, 2021, pp.6657012~ (2021)
- Li Y, "VSTM2L contributes to anoikis resistance and acts as a novel biomarker for metastasis and clinical outcome in ovarian cancer", Biochem Biophys Res Commun, 658, pp.107~115 (2023)
- Banales JM, "Cholangiocarcinoma 2020 : the next horizon in mechanisms and management", Nat Rev Gastroenterol Hepatol, 17, pp.557~588 (2020)
- Zhu J, "TGFBI protein high expression predicts poor prognosis in colorectal cancer patients", Int J Clin Exp Pathol, 8, pp.702~710 (2015)
- Pajares MJ, "TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients", Br J Cancer, 110, pp.1545~1551 (2014)
- Macias RIR, "The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma", Biochim Biophys Acta Mol Basis Dis, 1864, pp.1468~1477 (2018)
- Miwa M, "Analysis of new biomarkers for cholangiocarcinoma", J Hepatobiliary Pancreat Sci, 21, pp.397~398 (2014)
- Sim W, "Robust method for identification of prognostic gene signatures from gene expression profiles", Sci Rep, 7, pp.16926~ (2017)
- Lee J, "Soluble TGFBI aggravates the malignancy of cholangiocarcinoma through activation of the ITGB1 dependent PPARgamma signalling pathway", Cell Oncol(Dordr), 45, pp.275~291 (2022)
- Lee J, "Atypical induction of HIF-1alpha expression by pericellular Notch1 signaling suffices for the malignancy of glioblastoma multiforme cells", Cell Mol Life Sci, 79, pp.537~ (2022)
- Lee J, "Differential dependency of human glioblastoma cells on vascular endothelial growth factor‑A signaling via neuropilin‑1", Int J Oncol, 61, pp.122~ (2022)
- Lee J, "Differential dependency of human cancer cells on vascular endothelial growth factor-mediated autocrine growth and survival", Cancer Lett, 309, pp.145~150 (2011)